Literature DB >> 2479716

Identification of immunogenic regions of the major coat protein of human papillomavirus type 16 that contain type-restricted epitopes.

J Cason1, D Patel, J Naylor, D Lunney, P S Shepherd, J M Best, D J McCance.   

Abstract

We have identified regions of the major capsid protein, L1, of the human papillomavirus (HPV) type 16 (HPV-16 L1), that are recognized by five monoclonal antibodies (MAbs) raised to a bacterial fusion protein containing residues 172 to 375 of HPV-16 L1. All five MAbs recognized HPV-16-infected tissue sections by immunohistochemistry, but not sections infected with HPV-1a (cutaneous warts), HPV-6b or -11 (genital warts). MAbs 3D1, 5A4 and 1D6 also recognized HPV-2-infected sections (cutaneous warts); MAb 8C4 recognized only sections containing HPV-16. Four MAbs (8C4, 3D1, 1D6 and 5A4) recognized a synthetic peptide corresponding to residues 269 to 284 of HPV-16 L1; within this region a minimum antibody binding site was identified, a tripeptide 276 to 278. However the complete epitope appears to extend beyond these residues and beyond HPV-16 L1 (269 to 284). The fifth MAb, 1C6, recognized bacterial fusion proteins containing HPV-6b L1, -16 L1 or -18 L1 using immunoblots, yet appeared HPV-16-specific when tested on infected tissue sections. This MAb recognized five amino acids within a different region of HPV-16 L1 (residues 299 to 313).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2479716     DOI: 10.1099/0022-1317-70-11-2973

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  22 in total

1.  Simultaneous in situ genotyping and phenotyping of human papillomavirus cervical lesions: comparative sensitivity and specificity.

Authors:  A K Graham; C S Herrington; O McGee J
Journal:  J Clin Pathol       Date:  1991-02       Impact factor: 3.411

Review 2.  Cancer of the cervix: prospects for immunological control.

Authors:  D H Davies; G A McIndoe; B M Chain
Journal:  Int J Exp Pathol       Date:  1991-04       Impact factor: 1.925

3.  Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications.

Authors:  Maxime J J Fleury; Antoine Touzé; Marie-Christine Maurel; Thierry Moreau; Pierre Coursaget
Journal:  Protein Sci       Date:  2009-07       Impact factor: 6.725

Review 4.  Multiplicity of uses of monoclonal antibodies that define papillomavirus linear immunodominant epitopes.

Authors:  A B Jenson; M C Jenson; L Cowsert; S J Ghim; J P Sundberg
Journal:  Immunol Res       Date:  1997-02       Impact factor: 2.829

5.  Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth.

Authors:  D W Liu; Y P Tsao; C H Hsieh; J T Hsieh; J T Kung; C L Chiang; S J Huang; S L Chen
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

6.  Induction of immune responses against human papillomaviruses by hypervariable epitope constructs.

Authors:  K Jyotsna Reddy; Babak Banapour; David E Anderson; Sang H Lee; Juan P Marquez; Maria P Carlos; Jose V Torres
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

Review 7.  Pathobiology of papillomavirus-related cervical diseases: prospects for immunodiagnosis.

Authors:  C P Crum; S Barber; J K Roche
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

8.  Sequence variation in the L1 gene of human papillomavirus type 16 from Africa.

Authors:  J E Ramesar; E P Rybicki; A L Williamson
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

9.  Human papillomavirus type 16 infection of the cervix: a comparison of differing DNA detection modes and the use of monoclonal antibodies against the major capsid protein.

Authors:  C J Lacey; M Wells; R I Macdermott; P E Gibson
Journal:  Genitourin Med       Date:  1991-04

10.  Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses.

Authors:  Alba-Lucia Combita; Antoine Touzé; Latifa Bousarghin; Neil D Christensen; Pierre Coursaget
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.